investiment.io
Zoetis Stock Tumbles on Safety Concerns for Arthritis Shots for Pets
Zoetis Inc. experienced a sharp decline in its stock price following a report by The Wall Street Journal indicating potential harm to pets from its arthritis shots, Librela and Solensia, raising concerns among investors and prompting an investigation into possible violations of federal securities laws.
Zoetis Inc, a leading animal health company, saw its stock price plummet by around 8.4% to $149.12 midday Friday, following a report by The Wall Street Journal. The report raised concerns over the safety of the company's arthritis shots, Librela and Solensia, which are used to treat osteoarthritis in dogs and cats. According to the report, these medications, which target the nerve growth factor protein, could potentially worsen pre-existing nerve conditions or cause other medical issues in pets. Health regulators both in the United States and Europe have received numerous complaints regarding side effects from these drugs. Despite these reports, Zoetis responded by indicating that these adverse events only represent a small fraction of the over 18 million doses administered globally.
In response to the emerging concerns, the law firm Levi & Korsinsky has initiated an investigation into possible violations of federal securities laws by Zoetis Inc. following the significant drop in the company's stock value by more than 4% after the news was published on April 12, 2024. Levi & Korsinsky, a nationally-recognized securities litigation firm with a track record of securing substantial recoveries for shareholders and winning high-stakes cases, is urging investors who have suffered losses to contact them to discuss their legal rights. The firm has been ranked in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its prominence and success in securities litigation in the United States.
Zoetis's situation underscores the intricate balance companies must maintain between innovation in veterinary medicine and the imperative to ensure safety and efficacy. The investigation by Levi & Korsinsky not only seeks to address potential losses faced by Zoetis investors but also highlights the broader implications for regulatory oversight and consumer trust in veterinary pharmaceuticals. Investors and pet owners alike are keenly watching how Zoetis will navigate these legal and regulatory challenges, and what steps will be taken to ensure the safety of its products moving forward.
Articles published about this story
- accesswire.comaccesswire.com
- proactiveinvestors.comproactiveinvestors.com
- barrons.combarrons.com
- marketwatch.commarketwatch.com
- investors.cominvestors.com
More stories
- investiment.ioinvestiment.io
Meta Platforms (NASDAQ: META) faces a pivotal moment after recent earnings, as analysts cut price targets due to increased expenses for the Metaverse and AI. Despite the stock dip from AI spending concerns, analysts believe in Meta's strong core business and potential future profitability.
- investiment.ioinvestiment.io
U.S. regulators are seizing Republic First Bancorp and arranging for its sale, following the bank's struggles with high costs and profitability issues. The bank's operations will be transferred to Fulton Bank after regulatory approval.
- investiment.ioinvestiment.io
Chinese electric car start-ups Nio and Xpeng are expanding their market reach by introducing new affordable models, potentially boosting their competitiveness. This move comes amidst positive market sentiment towards China-based EV makers, driven by reports of government incentives for electric vehicle purchases.
- investiment.ioinvestiment.io
ResMed reports strong earnings, surpassing Wall Street expectations in fiscal Q3, leading to a significant increase in stock price and demand for its sleep apnea devices.
- investiment.ioinvestiment.io
Skechers Inc. experienced a significant boost in its stock price following an impressive first-quarter performance, with earnings surpassing expectations and record-breaking revenues of $2.25 billion. Analysts also raised the price target on the stock due to the company's strong international market presence and increasing direct-to-consumer sales.
- investiment.ioinvestiment.io
Tech giants like Microsoft and Alphabet surpass Wall Street expectations in their recent earnings reports, crediting their profits to investments in AI. The companies continue to prioritize AI, with Microsoft investing nearly $10 billion abroad to solidify its position in the market, driving chip stock increases.
- investiment.ioinvestiment.io
NatWest Group PLC saw a decline in mortgage lending and net interest income in the first quarter of 2024. Despite this, its profit fell less than expected, leading to a rise in shares as results exceeded forecasts, bringing them close to a five-year high. The government also reduced its stake in the company.
- investiment.ioinvestiment.io
Exxon Mobil's first-quarter earnings fell short of expectations due to declining refining margins and plummeting natural gas prices, impacting the industry.
- investiment.ioinvestiment.io
The core personal consumption expenditures price index rose by 0.3% in March, exceeding expectations, potentially impacting the S&P 500 outlook. This unexpected inflation increase may delay rate-cut decisions and raise concerns about sustained price pressures.
- investiment.ioinvestiment.io
The U.S. National Highway Traffic Safety Administration is investigating if Tesla's recall of over 2 million vehicles in December to enhance Autopilot safety measures is sufficient.